The syndrome in question, known as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), manifests a range of symptoms within 2 to 8 weeks after taking the drug.
The IPC, in its drug safety alert issued on November 30, has urged both consumers and healthcare professionals to exercise heightened vigilance concerning the potential adverse drug reaction (ADR) linked to Meftal. Meftal is commonly prescribed for conditions such as menstrual cramps and rheumatoid arthritis.
According to a preliminary analysis of adverse drug reactions sourced from the Pharmacovigilance Programme of India (PvPI) database, instances of DRESS syndrome have been identified. This syndrome involves severe idiosyncratic drug reactions with a protracted latency period. Healthcare professionals and consumers are strongly advised to closely monitor the possibility of encountering this adverse reaction during the use of Meftal.
Individuals are encouraged to promptly report any concerns to the national coordination center of the PvPI under the IPC. This can be done by filling out a form on the official website (www.ipc.gov.in) or via the Android mobile app ADR PvPI. Alternatively, concerns can be communicated through the PvPI Helpline at 1800-180-3024.
Meftal, primarily composed of Mefenamic acid, serves as a painkiller widely used for alleviating muscle and joint pain, period pain, sore throats, nerve pain, and muscle aches.
Ranu Jain
